CLASS I Drug recall · Reported 26 Aug 2020 · FDA Enforcement Report

Stimate (desmopressin acetate) Nasal Spray1.5 mg/mL glass recalled

Ferring Pharmaceuticals is recalling Stimate (desmopressin acetate) Nasal Spray1.5 mg/mL glass vial with spray cap, distributed nationwide in the US. The recall was initiated on 21 Jul 2020 and the FDA has classified it as Class I.

Check your package

Lot, batch or date codesLot # N14134C, exp. date 07 2020 N15378G, exp. date 09 2020 N17445N, exp. date 02 2020 P11326AA, exp. date 02 2021 P11326C, exp. date 02 2021 P13209L, exp. date 04 2021 P13212H, exp. date 06 2021 P13755A, exp. date 06 2021 P13756P, exp. date 08 2021 R11845A, exp. date 04 2022 R13271A, exp. date 04 2022 R13648A, exp. date 06 2022 R14101A, exp. date 07 2022 R14667A, exp. date 08 2022 R15953C, exp. date 09 2022
Quantity recalled29,371 nasal sprays

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1506-2020
FDA event ID
86066
Recalling firm
Ferring Pharmaceuticals, Parsippany, NJ
Classification
Class I
Status
Terminated
Recall initiated
21 Jul 2020
FDA classified
17 Aug 2020
Reported
26 Aug 2020
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay
Drug class
Nasal Sprays

Timeline

21 Jul 2020Recall initiated by company
17 Aug 2020Classified by FDA+27 days
26 Aug 2020Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Superpotent Drug

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

STIMATE (desmopressin acetate) Nasal Spray1.5 mg/mL, 2.5 mL glass vial with spray cap, Rx only, Manufactured for: CSL Behring LLC, King of Prussia, PA 19406-0901; By: Ferring GmbH, Kiel, Germany, NDC 0053-6871-00

Where it was distributed

Nationwide within the United States.

Nationwide

Questions about this recall

Why was it recalled?

Superpotent Drug

Which lots are affected?

Lot # N14134C, exp. date 07 2020 N15378G, exp. date 09 2020 N17445N, exp. date 02 2020 P11326AA, exp. date 02 2021 P11326C, exp. date 02 2021 P13209L, exp. date 04 2021 P13212H, exp. date 06 2021 P13755A, exp. date 06 2021 P13756P, exp. date 08 2021 R11845A, exp. date 04 2022 R13271A, exp. date 04 2022 R13648A, exp. date 06 2022 R14101A, exp. date 07 2022 R14667A, exp. date 08 2022 R15953C, exp. date 09 2022

Where was it sold?

Nationwide within the United States.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class I mean?

Class I is the most serious FDA recall category: there is a reasonable probability that using the product will cause serious health consequences or death.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

2 other products · FDA event 86066

More recalls from Ferring Pharmaceuticals

All 12